1. Development of an alcoholic liver disease model for drug evaluation from human induced pluripotent stem cell-derived liver organoids
- Author
-
Feng Zhiwei, Zhou Bingrui, Shuai Qizhi, Wei Yunliang, Jin Ning, Wang Xiaoling, Zhao Hong, Liu Zhizhen, Xu Jun, Mu Jianbing, and Xie Jun
- Subjects
human induced pluripotent stem cell ,liver organoid ,alcoholic liver disease ,drug screening ,Biochemistry ,QD415-436 ,Genetics ,QH426-470 - Abstract
Alcoholic liver disease (ALD) poses a significant health challenge, so comprehensive research efforts to improve our understanding and treatment strategies are needed. However, the development of effective treatments is hindered by the limitation of existing liver disease models. Liver organoids, characterized by their cellular complexity and three-dimensional (3D) tissue structure closely resembling the human liver, hold promise as ideal models for liver disease research. In this study, we use a meticulously designed protocol involving the differentiation of human induced pluripotent stem cells (hiPSCs) into liver organoids. This process incorporates a precise combination of cytokines and small molecule compounds within a 3D culture system to guide the differentiation process. Subsequently, these differentiated liver organoids are subject to ethanol treatment to induce ALD, thus establishing a disease model. A rigorous assessment through a series of experiments reveals that this model partially recapitulates key pathological features observed in clinical ALD, including cellular mitochondrial damage, elevated cellular reactive oxygen species (ROS) levels, fatty liver, and hepatocyte necrosis. In addition, this model offers potential use in screening drugs for ALD treatment. Overall, the liver organoid model of ALD, which is derived from hiPSC differentiation, has emerged as an invaluable platform for advancing our understanding and management of ALD in clinical settings.
- Published
- 2024
- Full Text
- View/download PDF